TY - GEN
T1 - Prevention of acute venous stent-induced thrombosis using inhibition of fxii
AU - Nguyen, Khanh P.
AU - Wallisch, Michael
AU - Johnson, Jennifer
AU - Gruber, András
AU - Hinds, Monica T.
N1 - Publisher Copyright:
© 2019 Omnipress - All rights reserved.
PY - 2019
Y1 - 2019
N2 - Acute proximal lower extremity deep vein thrombosis (DVT) affects 1-2 per 1000 patients annually and confers significant acute and chronic morbidity and mortality. Pulmonary embolism (PE) and post-thrombotic syndrome (PTS) remain prevalent and hard-to-manage complications after DVT despite medical therapy. Treatment and recanalization of symptomatic, iliofemoral venous stenosis or obstruction, the long-term sequelae of DVT and DVT-associated PTS, by angioplasty and stenting is indicated in select ambulatory patients. While venous stenting can improve and restore blood flow in some cases, patency rates are poor with 1-year patency rates of 70% and significantly lower 5-year patency rates. After stenting, medical management of DVT requires either anti-platelet therapy and/or anticoagulation, which improves primary patency rates but carries a significant, 2-4% annual risk of major bleeding. Modern anticoagulation therapy including vitamin K antagonists, direct thrombin inhibitors and Factor X inhibitors have significant bleeding risks due to the impairment of hemostasis. As many patients require long-term medical therapy, development of a novel anticoagulant with a lower risk profile is critical. Since coagulation factor XII (FXII) supports contact activation of blood but has no known contribution to hemostasis, we sought to determine the thrombogenic role of FXII in an acute ex vivo venous stent model utilizing a FXII-neutralizing monoclonal antibody, 5C12.
AB - Acute proximal lower extremity deep vein thrombosis (DVT) affects 1-2 per 1000 patients annually and confers significant acute and chronic morbidity and mortality. Pulmonary embolism (PE) and post-thrombotic syndrome (PTS) remain prevalent and hard-to-manage complications after DVT despite medical therapy. Treatment and recanalization of symptomatic, iliofemoral venous stenosis or obstruction, the long-term sequelae of DVT and DVT-associated PTS, by angioplasty and stenting is indicated in select ambulatory patients. While venous stenting can improve and restore blood flow in some cases, patency rates are poor with 1-year patency rates of 70% and significantly lower 5-year patency rates. After stenting, medical management of DVT requires either anti-platelet therapy and/or anticoagulation, which improves primary patency rates but carries a significant, 2-4% annual risk of major bleeding. Modern anticoagulation therapy including vitamin K antagonists, direct thrombin inhibitors and Factor X inhibitors have significant bleeding risks due to the impairment of hemostasis. As many patients require long-term medical therapy, development of a novel anticoagulant with a lower risk profile is critical. Since coagulation factor XII (FXII) supports contact activation of blood but has no known contribution to hemostasis, we sought to determine the thrombogenic role of FXII in an acute ex vivo venous stent model utilizing a FXII-neutralizing monoclonal antibody, 5C12.
UR - http://www.scopus.com/inward/record.url?scp=85065386728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065386728&partnerID=8YFLogxK
M3 - Conference contribution
AN - SCOPUS:85065386728
T3 - Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium
SP - 20
BT - Society for Biomaterials Annual Meeting and Exposition 2019
PB - Society for Biomaterials
T2 - 42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence
Y2 - 3 April 2019 through 6 April 2019
ER -